Alentis and PinotBio partner to develop claudin-1 oncology ADCs

​

Alentis Therapeutics and PinotBio have entered into a research collaboration and licensing agreement to develop claudin-1-targeting antibody-drug conjugates (ADCs) for oncology indications.

The post Alentis and PinotBio partner to develop claudin-1 oncology ADCs appeared first on Hospital Management.

 

Back to the Featured Stories
Alentis and PinotBio partner to develop claudin-1 oncology ADCs

Featured Stories

FDA approves Stryker’s Sonopet 3 surgical platform
Pilatus doses first patient in Phase I PLT012 trial for HCC
Butterfly Medical secures EU MDR certification for BPH implant
Dosing completed in Calluna Pharma’s Phase II AURORA trial
Pfizer partners with Enodia Therapeutics in $500m drug deal

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us